431 related articles for article (PubMed ID: 21555250)
1. Treatment of multiple sclerosis with anti-CD20 antibodies.
Barun B; Bar-Or A
Clin Immunol; 2012 Jan; 142(1):31-7. PubMed ID: 21555250
[TBL] [Abstract][Full Text] [Related]
2. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.
Frisch ES; Pretzsch R; Weber MS
Neurotherapeutics; 2021 Jul; 18(3):1602-1622. PubMed ID: 33880738
[TBL] [Abstract][Full Text] [Related]
3. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
4. Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121.
Taupin P
Expert Opin Ther Pat; 2011 Jan; 21(1):111-4. PubMed ID: 21155688
[TBL] [Abstract][Full Text] [Related]
5. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.
Cross AH; Stark JL; Lauber J; Ramsbottom MJ; Lyons JA
J Neuroimmunol; 2006 Nov; 180(1-2):63-70. PubMed ID: 16904756
[TBL] [Abstract][Full Text] [Related]
6. Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies.
Gasperini C; Haggiag S; Ruggieri S
Expert Opin Investig Drugs; 2013 Oct; 22(10):1243-53. PubMed ID: 23855792
[TBL] [Abstract][Full Text] [Related]
7. Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis.
Sefia E; Pryce G; Meier UC; Giovannoni G; Baker D
Mult Scler Relat Disord; 2017 May; 14():46-50. PubMed ID: 28619431
[TBL] [Abstract][Full Text] [Related]
8. Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
Klotz L; Meuth SG; Wiendl H
Clin Immunol; 2012 Jan; 142(1):25-30. PubMed ID: 21550857
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD20 monoclonal antibodies: beyond B-cells.
Avivi I; Stroopinsky D; Katz T
Blood Rev; 2013 Sep; 27(5):217-23. PubMed ID: 23953071
[TBL] [Abstract][Full Text] [Related]
10. B cell-directed therapies in multiple sclerosis.
Gasperi C; Stüve O; Hemmer B
Neurodegener Dis Manag; 2016; 6(1):37-47. PubMed ID: 26782316
[TBL] [Abstract][Full Text] [Related]
11. The use of monoclonal antibodies in immune-mediated hematologic disorders.
Dierickx D; Beke E; Devos T; Delannoy A
Med Clin North Am; 2012 May; 96(3):583-619, xi. PubMed ID: 22703857
[TBL] [Abstract][Full Text] [Related]
12. CD20-targeted therapy: the next generation of antibodies.
van Meerten T; Hagenbeek A
Semin Hematol; 2010 Apr; 47(2):199-210. PubMed ID: 20350667
[TBL] [Abstract][Full Text] [Related]
13. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Hauser SL; Waubant E; Arnold DL; Vollmer T; Antel J; Fox RJ; Bar-Or A; Panzara M; Sarkar N; Agarwal S; Langer-Gould A; Smith CH;
N Engl J Med; 2008 Feb; 358(7):676-88. PubMed ID: 18272891
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma.
Heinrich DA; Weinkauf M; Hutter G; Zimmermann Y; Jurinovic V; Hiddemann W; Dreyling M
Br J Haematol; 2015 Feb; 168(4):606-10. PubMed ID: 25292485
[No Abstract] [Full Text] [Related]
15. B-Cell Depletion - A Frontier in Monoclonal Antibodies for Multiple Sclerosis.
Calabresi PA
N Engl J Med; 2017 Jan; 376(3):280-282. PubMed ID: 28001486
[No Abstract] [Full Text] [Related]
16. B cells in multiple sclerosis therapy-A comprehensive review.
Rahmanzadeh R; Weber MS; Brück W; Navardi S; Sahraian MA
Acta Neurol Scand; 2018 Jun; 137(6):544-556. PubMed ID: 29512131
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.
Rossi EA; Chang CH; Goldenberg DM
PLoS One; 2014; 9(5):e98315. PubMed ID: 24841238
[TBL] [Abstract][Full Text] [Related]
18. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.
Ancau M; Berthele A; Hemmer B
Expert Opin Biol Ther; 2019 Aug; 19(8):829-843. PubMed ID: 31027436
[TBL] [Abstract][Full Text] [Related]
19. The future of anti-CD20 monoclonal antibodies: are we making progress?
Alduaij W; Illidge TM
Blood; 2011 Mar; 117(11):2993-3001. PubMed ID: 21209380
[TBL] [Abstract][Full Text] [Related]
20. B cell depletion in the treatment of multiple sclerosis.
Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]